A new review published in Research on February 5, 2026, explores the potential of bacterial extracellular vesicles as next-generation therapeutic platforms for fighting infections.
The Science Behind BEVs
Bacterial extracellular vesicles (BEVs) are nanosized, lipid-bound particles naturally secreted by bacteria. They contain bioactive molecules such as proteins, nucleic acids, and metabolites.
The review notes that natural BEVs have intrinsic antibacterial capabilities, including delivering enzymes that break down bacterial cell walls and inhibiting biofilm formation. BEVs can also interfere with bacterial adhesion to host tissues.
Engineering a New Class of Therapeutics
Led by Professor Honggang Hu and Dr. Yejiao Shi from Shanghai University, and Professor Cuiping Zhang and Dr. Xi Liu from PLA General Hospital, the research examines how BEVs can be engineered to kill pathogens, block infection, enhance vaccines, and deliver drugs.
Engineering strategies discussed include:
- Genetic modification of bacteria to produce BEVs with reduced toxicity or enhanced antigen presentation
- Physical and chemical methods to load drugs or attach targeting molecules
The review suggests that engineered BEVs could serve as vaccine platforms, immune adjuvants, and targeted drug delivery systems.
Challenges and Future Directions
The authors note that challenges remain, including variability in BEV composition, lack of standardized production methods, and safety concerns. Advances in multiomics analysis and AI-driven design are expected to help address these barriers.